靶向HER2-话题@MedSci

#靶向HER2#

8篇内容 | 275人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1819800, encodeId=378b18198008c, content=<a href='/topic/show?id=b4e2998897f' target=_blank style='color:#2F92EE;'>#靶向HER2#</a>, objectTitle=靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌, objectType=article, longId=221117, objectId=796122111e42, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=796122111e42, replyNumber=0, likeNumber=41, createdTime=2022-01-29, rootId=0, userName=smallant2002, userId=0a27288, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=796122111e42, moduleTitle=靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=796122111e42)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1819799, encodeId=0add1819e9925, content=<a href='/topic/show?id=b4e2998897f' target=_blank style='color:#2F92EE;'>#靶向HER2#</a>, objectTitle=Br J Cancer：三种靶向HER2的酪氨酸激酶抑制剂的比较分析, objectType=article, longId=206381, objectId=297020638150, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=297020638150, replyNumber=0, likeNumber=46, createdTime=2021-05-31, rootId=0, userName=smallant2002, userId=0a27288, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=297020638150, moduleTitle=Br J Cancer：三种靶向HER2的酪氨酸激酶抑制剂的比较分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=297020638150)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1819798, encodeId=a8341819e988f, content=<a href='/topic/show?id=b4e2998897f' target=_blank style='color:#2F92EE;'>#靶向HER2#</a>, objectTitle=靶向HER2的抗体药物偶联物ENHERTU治疗乳腺癌，获得欧洲药品管理局的快速审查, objectType=article, longId=197261, objectId=e32219e26199, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e32219e26199, replyNumber=0, likeNumber=43, createdTime=2021-04-26, rootId=0, userName=smallant2002, userId=0a27288, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e32219e26199, moduleTitle=靶向HER2的抗体药物偶联物ENHERTU治疗乳腺癌，获得欧洲药品管理局的快速审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e32219e26199)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1819797, encodeId=1a3a1819e9794, content=<a href='/topic/show?id=b4e2998897f' target=_blank style='color:#2F92EE;'>#靶向HER2#</a>, objectTitle=FDA批准罗氏的乳腺癌双靶向HER2抗体组合：帕妥珠单抗与曲妥珠单抗, objectType=article, longId=196865, objectId=2899196865f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2899196865f2, replyNumber=0, likeNumber=29, createdTime=2021-04-16, rootId=0, userName=smallant2002, userId=0a27288, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2899196865f2, moduleTitle=FDA批准罗氏的乳腺癌双靶向HER2抗体组合：帕妥珠单抗与曲妥珠单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2899196865f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1819796, encodeId=02aa1819e96b2, content=<a href='/topic/show?id=b4e2998897f' target=_blank style='color:#2F92EE;'>#靶向HER2#</a>, objectTitle=靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌, objectType=article, longId=194432, objectId=19de1944327b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19de1944327b, replyNumber=0, likeNumber=39, createdTime=2021-01-02, rootId=0, userName=smallant2002, userId=0a27288, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19de1944327b, moduleTitle=靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19de1944327b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1819795, encodeId=f8981819e95cd, content=<a href='/topic/show?id=b4e2998897f' target=_blank style='color:#2F92EE;'>#靶向HER2#</a>, objectTitle=FDA授予靶向HER2的抗体药物偶联物ENHERTU突破性疗法称号，以治疗HER2阳性转移性胃癌, objectType=article, longId=194130, objectId=0b9d19413073, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b9d19413073, replyNumber=0, likeNumber=33, createdTime=2020-11-06, rootId=0, userName=smallant2002, userId=0a27288, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b9d19413073, moduleTitle=FDA授予靶向HER2的抗体药物偶联物ENHERTU突破性疗法称号，以治疗HER2阳性转移性胃癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b9d19413073)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1819794, encodeId=1a6b1819e9446, content=<a href='/topic/show?id=b4e2998897f' target=_blank style='color:#2F92EE;'>#靶向HER2#</a>, objectTitle=靶向HER2的抗体偶联药物ADC治疗转移性乳腺癌获得FDA的优先审查, objectType=article, longId=181781, objectId=1e9c181e813c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e9c181e813c, replyNumber=0, likeNumber=33, createdTime=2019-11-27, rootId=0, userName=smallant2002, userId=0a27288, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e9c181e813c, moduleTitle=靶向HER2的抗体偶联药物ADC治疗转移性乳腺癌获得FDA的优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e9c181e813c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1819793, encodeId=74ad1819e931f, content=<a href='/topic/show?id=b4e2998897f' target=_blank style='color:#2F92EE;'>#靶向HER2#</a>, objectTitle=阿斯利康靶向HER2的抗体药物偶联物在II期临床试验中显示出治疗前景, objectType=article, longId=165882, objectId=9c0116588208, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c0116588208, replyNumber=0, likeNumber=27, createdTime=2019-08-14, rootId=0, userName=smallant2002, userId=0a27288, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c0116588208, moduleTitle=阿斯利康靶向HER2的抗体药物偶联物在II期临床试验中显示出治疗前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c0116588208)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

靶向HER2

2020-05-29

smallant2002 (审核中...)

前往app查看评论内容

#靶向HER2#

靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌

2022-01-29

smallant2002 (审核中...)

前往app查看评论内容

#靶向HER2#

Br J Cancer：三种靶向HER2的酪氨酸激酶抑制剂的比较分析

2021-05-31

smallant2002 (审核中...)

前往app查看评论内容

#靶向HER2#

靶向HER2的抗体药物偶联物ENHERTU治疗乳腺癌，获得欧洲药品管理局的快速审查

2021-04-26

smallant2002 (审核中...)

前往app查看评论内容

#靶向HER2#

FDA批准罗氏的乳腺癌双靶向HER2抗体组合：帕妥珠单抗与曲妥珠单抗

2021-04-16

smallant2002 (审核中...)

前往app查看评论内容

#靶向HER2#

靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌

2021-01-02

smallant2002 (审核中...)

前往app查看评论内容

#靶向HER2#

FDA授予靶向HER2的抗体药物偶联物ENHERTU突破性疗法称号，以治疗HER2阳性转移性胃癌

2020-11-06

smallant2002 (审核中...)

前往app查看评论内容

#靶向HER2#

靶向HER2的抗体偶联药物ADC治疗转移性乳腺癌获得FDA的优先审查

2019-11-27

smallant2002 (审核中...)

前往app查看评论内容

#靶向HER2#

阿斯利康靶向HER2的抗体药物偶联物在II期临床试验中显示出治疗前景

2019-08-14

科室
- - 订阅+
  - 更多科室
工具
服务